Completed PHASE4 INTERVENTIONAL 2-arm NCT00817648

A Study to Evaluate the Efficacy and Safety of Seroquel in Chinese Han Patients With Schizophrenia

A 6-Week, Multicenter, Rater-blind, Randomized, Risperidone-controlled Study to Evaluate the Efficacy and Safety of Seroquel (Quetiapine Fumarate) in the Treatment of Chinese Han Patients With Schizophrenia

Sponsor: Shanghai Mental Health Center

Conditions Schizophrenia

Interventions Quetiapine risperidone

Updated 5 times since 2017 Last updated: Jun 11, 2010 Started: Dec 31, 2008 Primary completion: May 31, 2010 Completion: May 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Schizophrenia, this trial is completed. The trial is conducted by Shanghai Mental Health Center and has accumulated 5 data snapshots since 2008. Psychiatric clinical trials are essential for establishing evidence-based treatment standards.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Dec 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shanghai Mental Health Center

Data source: Shanghai Mental Health Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Huzhou, China
• Shanghai, China